If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Biopharmaceuticals : Gates Foundation Funds Liquidia’s Vaccine Development Program

by Rick Mullin
March 14, 2011 | A version of this story appeared in Volume 89, Issue 11

Liquidia Technologies, a drug delivery start-up launched from the University of North Carolina, Chapel Hill, has received a $10 million equity investment from the Bill & Melinda Gates Foundation to further the firm’s vaccine development program. The Liquidia investment is the foundation’s first in a health-care-related biotech firm.

Joseph DeSimone, a chemistry professor at UNC and founder of Liquidia, says he met with Bill Gates last year at a private investors’ conference where DeSimone outlined the firm’s lithography-based technology for regulating drug and vaccine particle size and shape. Liquidia’s particle replication in nonwetting templates (PRINT) technology uses silicon wafers and a fluoropolymer mold to form particles, a technique similar to lithography used in manufacturing computer chips.

The PRINT technology, though focused on particle formation, enables a range of chemical syntheses in the development of vaccines and drugs. The company’s lead product is LIQ001, a seasonal flu vaccine for elderly patients. It is currently in Phase I clinical trials.

The Gates Foundation made the investment under its two-year-old program-related investments initiative. Under the $400 million initiative, the foundation evaluates a range of opportunities, including equity investments in funds and purchases of shares in companies.

The Gates Foundation will take an undisclosed stake in Liquidia as well as a nonvoting, advisory seat on the company’s board. The firm has raised about $60 million, including the Gates investment.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.